Joana Carvalho, PhD,  managing science editor—

The University of Portsmouth, U.K., is partnering with Josh Llewellyn-Jones, a record-breaking endurance athlete who has cystic fibrosis (CF), to drive a scientific PhD research program that aspires to improve the lives of people with the disease. Llewellyn-Jones defied the odds by living past his 30s and…

The Cystic Fibrosis Foundation has given an additional $1.8 million to support early toxicology studies of pravibismane, Microbion’s investigational inhaled therapy for lung infections in people with cystic fibrosis (CF).  Data from these early toxicology studies, expected to conclude by mid-year, could support regulatory requests to…

The National Institute for Health Research (NIHR) awarded a grant worth more than £1.5 million (about $2.1 million) to support a U.K. clinical trial investigating ways of safely lowering the treatment burden of cystic fibrosis (CF), a top priority for patients and their healthcare teams. The randomized and open-label…

Higher doses of vitamin D supplements do not appear to lead to better clinical outcomes, either in lung function or bone health, in people with cystic fibrosis (CF), a systematic review reported. Because this crucial vitamin is lacking in patients, however, further studies evaluating the long-term effects of vitamin…

Hospitalized children and adolescents with cystic fibrosis (CF) who can take enzyme treatments for pancreatic insufficiency on their own, rather than waiting for them to be given by a nurse, are more likely to take these necessary medications at the proper time with less of a wait, a survey…

A species of antibiotic-producing bacteria able to inhibit the growth of antibiotic-resistant bacteria linked to chronic lung infections — found in the soils of Northern Ireland and long used in traditional medicine there — have been isolated and shown to have antimicrobial activity, researchers report. The bacteria whose growth they…

U.K. Rare Diseases Framework, a government-led approach to raising national awareness of rare disorders, accelerating  diagnoses, and improving patient care and treatment, is now in practice. This  framework, signed by all four countries take make up the U.K. — England, Scotland, Wales and Northern Ireland — builds on the success…

When given alongside the antibiotic Colistin (colistimethate), Cayston (aztreonam lysine), an inhaled antibiotic specifically targeting Pseudomonas aeruginosa, was superior to standard intravenous antibiotics at improving lung function and life quality among adults with cystic fibrosis (CF) and lung infections due to P. aeruginosa during an acute flare, a single-site…

Arcturus Therapeutics has selected ARCT-032, an aerosolized RNA-based therapy, to be developed as a novel therapeutic candidate for cystic fibrosis (CF). The therapy will use the company’s LUNAR delivery technology that comprises a library of more than 150 proprietary fatty molecules specifically designed to deliver RNA-based therapies…

Scientists discovered the subtypes of gentamicin — a broad-spectrum antibiotic often used to treat bacterial infections in people with cystic fibrosis (CF) — that are more likely to cause deafness, and created a new formulation that is as effective at eliminating bacteria but much safer for patients. “We’ve developed…